Recent advances in the noninvasive diagnosis of renal osteodystrophy

Kidney International

Volumn 84, Issue 5, 2013, Pages 886-894

  Moorthi, Ranjani N ^a   Moe, Sharon M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bone biomarker; bone quality; CKD MBD; dual X ray absorptiometry; parathyroid hormone; renal osteodystrophy

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; PARATHYROID HORMONE; PROCOLLAGEN TYPE 1C PROPEPTIDE; PROCOLLAGEN TYPE 1N PROPEPTIDE; SCLEROSTIN; TATRATE RESISTANT ACID PHOSPHATASE 5B; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

BONE BIOPSY; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HIGH RESOLUTION PERIPHERAL COMPUTERIZED TOMOGRAPHY; HUMAN; MEDICAL RESEARCH; MICRO-COMPUTED TOMOGRAPHY; MICROFRACTURE; MORPHOMETRICS; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERIPHERAL QUANTITATIVE COMPUTERIZED TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE COMPUTERIZED TOMOGRAPHY; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; SPECTROSCOPY;

ABSORPTIOMETRY, PHOTON; BIOLOGICAL MARKERS; BIOPSY; BONE AND BONES; BONE DENSITY; BONE REMODELING; DIAGNOSTIC IMAGING; FRACTURES, BONE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL OSTEODYSTROPHY; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84888323995     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.254     Document Type: Review

References (75)

1. Lucas RC. On a form of late rickets associated with albuminuria. Lancet 1883; 1: 993-994.
2. Liu SH, Chu HI. Treatment of renal osteodystrophy with dihydrotachysterol (A.T.10) and iron. Science 1942; 95: 388-389.
3. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
4. Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 2002; 30: 5-7.
5. Sprague SM. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial 2000; 13: 152-155.
6. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what's in a name Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol 2006; 65: 235-242.
7. Barreto FC, Barreto DV, Moyses RM et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 2006; 69: 1852-1857.
8. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399.
9. Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis 2008; 51: 38-44.
10. Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. Arthritis Rheum 2001; 44: 1496-1503.
11. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in endstage renal failure-an evolving disorder. Kidney Int 1993; 43: 436-442.
12. Jorgetti V. Review article: Bone biopsy in chronic kidney disease: patient level end-point or just another test Nephrology (Carlton) 2009; 14: 404-407.
13. Batista DG, Neves KR, Graciolli FG et al. The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances. Calcif Tissue Int 2010; 87: 60-67.
14. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996; 11(Suppl 3): 111-120.
15. Parfitt AM. A structural approach to renal bone disease. J Bone Miner Res 1998; 13: 1213-1220.
16. Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002; 17: 1741-1743.
17. Leonard MB. A structural approach to skeletal fragility in chronic kidney disease. Semin Nephrol 2009; 29: 133-143.
18. Hind K, Oldroyd B, Truscott JG. In vivo precision of the GE Lunar iDXA densitometer for the measurement of total-body, lumbar spine, and femoral bone mineral density in adults. J Clin Densitom 2010; 13: 413-417.
19. Genant HK, Cooper C, Poor G et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999; 10: 259-264.
20. Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81: 1804-1809.
21. Chesnut CH 3rd, Rose CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001; 16: 2163-2172.
22. KDIGO. Clinical Practice Guidelines for the Management of CKD-MBD. Kidney Int 2009; 76: S1-S130.
23. Miller PD, Roux C, Boonen S et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20: 2105-2115.
24. Miller PD, Schwartz EN, Chen P et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007; 18: 59-68.
25. Aurora AB, Mahmoud AI, Luo X et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(\+) overload and cell death. JClin Invest 2012; 122: 1222-1232.
26. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49: 674-681.
27. Ambrus C, Almasi C, Berta K et al. Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol 2011; 43: 475-482.
28. Yenchek RH, Ix JH, Shlipak MG et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012; 7: 1130-1136.
29. Torres A, Lorenzo V, Gonzalez-Posada JM. Comparison of histomorphometry and computerized tomography of the spine in quantitating trabecular bone in renal osteodystrophy. Nephron 1986; 44: 282-287.
30. Mares J, Ohlidalova K, Opatrna S et al. Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients. J Bone Miner Metab 2009; 27: 217-223.
31. Jamal SA, Gilbert J, Gordon C et al. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 2006; 21: 543-548.
32. Cejka D, Patsch JM, Weber M et al. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol 2011; 6: 2264-2271.
33. West SL, Jamal SA. Determination of bone architecture and strength in men and women with stage 5 chronic kidney disease. Semin Dial 2012; 25: 397-402.
34. Nickolas TL, Stein E, Cohen A et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 2010; 21: 1371-1380.
35. Jamal SA, Cheung AM, West SL et al. Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int 2012; 23: 2805-2813.
36. van Rietbergen B, Weinans H, Huiskes R et al. A new method to determine trabecular bone elastic properties and loading using micromechanical finite-element models. J Biomech 1995; 28: 69-81.
37. Trombetti A, Stoermann C, Chevalley T et al. Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int 2012; 24: 1221-1732.
38. Link TM, Saborowski Kisters K, Kempkes M et al. Changes in calcaneal trabecular bone structure assessed with high-resolution MR imaging in patients with kidney transplantation. Osteoporos Int 2002; 13: 119-129.
39. Wehrli FW, Leonard MB, Saha PK et al. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imaging 2004; 20: 83-89.
40. Allen MR, Chen NX, Gattone VH 2nd et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int 2012; 24: 1471-1481.
41. Tchanque-Fossuo CN, Gong B, Poushanchi B et al. Raman spectroscopy demonstrates Amifostine induced preservation of bone mineralization patterns in the irradiated murine mandible. Bone 2012; 52: 712-717.
42. Morris MD, Mandair GS. Raman assessment of bone quality. Clin Orthop Relat Res 2011; 469: 2160-2169.
43. Wallace JM. Applications of atomic force microscopy for the assessment of nanoscale morphological and mechanical properties of bone. Bone 2012; 50: 420-427.
44. Hofbauer LC, Khosla S, Dunstan CR et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12.
45. B-fE Malluche HH, Rojas E, Carvalho AB et al. Predictive value of biomarkers for bone turnover in ESKDAbstract presentation, Renal Week 2010, American Society of Nephrology; 11/16/2010; Denver, CO, 2010.
46. Institute of Medicine. Dietary References Intakes: Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academy Press 1997.
47. Zidehsarai MP, Moe SM. Review article: Chronic kidney disease-mineral bone disorder: have we got the assays right Nephrology (Carlton) 2009; 14: 374-382.
48. Moorthi RN, Kandula P, Moe SM. Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question. Curr Opin Nephrol Hypertens 2011; 20: 354-359.
49. Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem 2012; 45: 920-927.
50. Alvarez L, Torregrosa JV, Peris P et al. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J Bone Miner Metab 2004; 22: 254-259.
51. Ohashi T, Igarashi Y, Mochizuki Y et al. Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 2007; 376: 205-212.
52. Yamada S, Inaba M, Kurajoh M et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol 2008; 69: 189-196.
53. Hannon RA, Clowes JA, Eagleton AC et al. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004; 34: 187-194.
54. Nickolas TL, Cremers S, Zhang A et al. Discriminants of prevalent fractures in chronic kidney disease. J AmSoc Nephrol 2011; 22: 1560-1572.
55. Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol 2010; 25: 603-608.
56. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517.
57. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
58. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
59. Winkler DG, Sutherland MK, Geoghegan JC et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267-6276.
60. Pelletier S, Dubourg L, Carlier MC et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819-823.
61. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882.
62. Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230.
63. Gardham C, Stevens PE, Delaney MP et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010; 5: 1261-1267.
64. Lehmann G, Stein G, Huller M et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68: 1206-1214.
65. Herberth J, Branscum AJ, Mawad H et al. Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study. Am J Kidney Dis 2010; 55: 897-906.
66. KDIGO: clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; S1-130.
67. Sawaya BP, Butros R, Naqvi S et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 2003; 64: 737-742.
68. Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156.
69. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
70. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
71. Rudser KD, de Boer IH, Dooley A et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407.
72. Sardiwal S, Gardham C, Coleman AE et al. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012; 82: 100-105.
73. Urena P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512.
74. Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-2302.
75. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655-663.